troglitazone has been researched along with Leukemia, Acute Monocytic in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Niu, Z | 1 |
| Tang, J | 1 |
| Zhang, W | 1 |
| Chen, Y | 1 |
| Huang, Y | 1 |
| Chen, B | 1 |
| Li, J | 1 |
| Shen, P | 1 |
1 other study available for troglitazone and Leukemia, Acute Monocytic
| Article | Year |
|---|---|
Caspase-1 promotes monocyte-macrophage differentiation by repressing PPARĪ³.
Topics: Binding Sites; Caspase 1; Cell Differentiation; Chromans; Gene Expression Regulation; Humans; Hypogl | 2017 |